A recent shortage of intravenous solutions underscores the need to address the fragile supply chain for infusion therapy ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Leqembi’s launch in the US has been slow due to a variety of factors including regular infusion logistics and diagnosis ...

First randomized placebo-controlled trial in NTM abscessusSymptom-based endpoints showed favorable improvement in frequency and severity of the most common symptomsMicrobiologic endpoints showed ...